Smith & Nephew Launches Innovative TRIGEN INTERTAN Nail for Femoral Fractures

12 July 2006

Smith & Nephew's (NYSE: SNN, LSE: SN) Orthopaedic Trauma & Clinical Therapies division today announced the launch of the TRIGEN◊ INTERTAN◊ Intertrochanteric Antegrade Nail for the treatment of femoral fractures.

The TRIGEN◊ INTERTAN◊ nail is indicated for the treatment of femoral fractures, or a break in the thigh bone, which runs from the hip to the knee and is the longest and strongest bone in the body. A femoral fracture is typically caused by direct trauma to the bone and requires an average of six to eight weeks to heal. There are approximately 250,000 hip fractures a year in the U.S.; hip fractures are expected to double to 500,000 by 2040.

The TRIGEN◊ INTERTAN◊ nail features an innovative two-screw configuration that secures the nail in place after surgery, acting together to provide greater stability for the bone and reduced healing time. Previous generations of intramedullary nails for femoral fractures used a single screw that sometimes contributed to a loosening of the device.

Smith & Nephew's development engineers, as well as a team of surgeons including Dr. Toney Russell of Memphis, Tennessee, designed and developed the TRIGEN◊ INTERTAN◊ nail and its two screw system. With more than 200 clinical cases already completed, the improved results include earlier weight bearing by patients and shorter healing times.

Mark Augusti, president of Smith & Nephew Orthopaedic Trauma & Clinical Therapies commented, "The TRIGEN◊ INTERTAN◊ nail's innovative design provides surgeons with greater options to treat their patients, and is a significant addition to our proprietary TRIGEN◊ portfolio."

About us

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Trauma & Clinical Therapies, Orthopaedic Reconstruction, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has over 8,500 employees and operates in 33 countries around the world generating annual sales of $2.6 billion in 2005.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.


Victor Rocha